Similar to the US arrangement, Ocugen will retain 45 per cent of the profit from sales of Covaxin in Canada.
Ocugen Inc, the US partner for Bharat Biotech’s COVID-19 vaccine has announced the payment of $15 million upfront to the Indian drug maker for extending the vaccine rights to Canada.
Ocugen in a regulatory filing said it has agreed to pay another $10 million to Bharat Biotech within a month from the commercial launch of Covaxin in the North American country.